


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: WU et al.
Serial No.: 09/904,251
Filed: 12 July 2001

Examiner: unknown
Group Art Unit: unknown
Docket: 9555.94USII



THE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION,
AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Office of Initial Patent Examination, Commissioner for Patents, Washington, D.C. 20231, on 24 October 2001.

By:

Heidi Hanson

Office of Initial Patent Examination
Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 58 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.


MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By:

Name: Gregory A. Sebald
Reg. No.: 33,280
GAS:hjh



(PTO TRANSMITTAL - GENERAL)



S/N 09/904251

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	WU et al.	Examiner:	unknown
Serial No.:	09/904251	Group Art Unit:	unknown
Filed:	12 July 2001	Docket No.:	9555.94USI1
Title:	USE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION, AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on 24 October 2001.

By:

Heidi Hanson

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2) and § 1.98(d), copies have been provided only for those items listed on the enclosed Form 1449 that have not previously been cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 09/341,009 filed on 25 August 1999.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or

otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: 24 October 2001

By



Gregory A. Sebald
Reg. No. 33,280

GAS:hjh